Novo Nordisk isn't just absorbing hurtful blows, though; it's been busy shoring up its defenses. As 2024 came to a close, it scooped up contract drug manufacturer Catalent, bringing Wegovy ...

Novo Nordisk is requesting a stop to all alleged false advertisement, trademark infringement, and compounded semaglutide products from these businesses.

Novo Nordisk stock ended 2021 at 56 and nearly tripled over the next three years. Wegovy became a blockbuster drug in 2023, shooting from $885 million in 2022 sales to almost $4.57 billion.

First, Novo Nordisk, the company behind Ozempic and Wegovy, outgrew its native Denmark. Now, it’s bigger than Tesla. Shares in the pharmaceutical giant rose jumped more than 8% Thursday, pushing ...

Novo Nordisk (NYSE: NVO) has been growing in popularity as a result of two incredibly popular drugs, Ozempic and Wegovy. Because of the company's phenomenal growth, it has been a top buy for many ...

Citing “unprecedented demand,” drugmaker Novo Nordisk said Thursday it expects supply restrictions on starter doses of the weight loss medicine Wegovy to persist into 2024, several months ...

Danish drug manufacturer Novo Nordisk announced a $4.1 billion investment to expand its U.S. manufacturing capacity in Clayton, North Carolina. In one of the largest investments in the firm's ...

Novo Nordisk recently launched Wegovy in the United Kingdom. Novo Nordisk (NVO 2.80%) has a couple of promising drugs in its portfolio that have made it a red-hot stock to own.

LONDON, April 24 (Reuters) - Since launching its wildly popular weight-loss drug Wegovy in 2021, Novo Nordisk (NOVOb.CO) has raised its annual sales guidance several times a year.

Novo Nordisk has grown its dividend at a compound annual growth rate (CAGR) of 7.6% over the past five years, falling well behind its earnings growth rate of 49.7% over the same period.

Novo Nordisk’s weighty valuation could be headed for a crash diet. On Thursday, the maker of diabetes and obesity remedies was worth over $270 billion, twice its value only two years ago.

Novo Nordisk’s obesity drug Wegovy cut the risk of major heart complications by 20% in a closely watched trial, results that could streamline insurance coverage and spur even greater demand for ...